QbDVision

QbDivision, Inc. operates a digital platform that enhances product life cycle management for the pharmaceutical and biotechnology industries, streamlining data management and process intelligence for developers. QbDivision, Inc. was founded in 2016 in Austin, US, providing solutions that facilitate product development in the pharmaceutical sector.

The company has engaged in 4 deals, with the most recent deal occurring on May 2025. They raised USD 13. 00 mn in venture funding during this round, co-led by Northpond Ventures and S3 Ventures, with participation from Create Health Ventures. The company has no publicly known subsidiaries or parent companies.

The founder's previous experience is not detailed. QbDVision provides a structured digital platform designed to streamline the product life cycle management process within the pharmaceutical and biotechnology sectors. The core offering includes a cloud-based hub that aggregates various data and knowledge across teams, creating a centralized source of truth for every unit and function. This platform is engineered to facilitate faster development, enhance knowledge management, and improve process intelligence, allowing users to make informed strategic decisions.

The software addresses critical challenges faced by drug developers, such as inefficient data management and complex tech transfer processes. QbDVision serves a global client base, including biopharma companies in North America, Europe, and Asia, all seeking to optimize their development workflows and enhance product quality. QbDVision's revenue model primarily operates on a subscription basis, allowing clients to access its suite of digital CMC solutions tailored for biotech processes. Clients typically engage with the platform through annual subscription plans, which may vary based on the size of the organization and the specific services utilized.

The company also engages in partnerships with industry players that seek to leverage QbDVision's capabilities for enhanced process knowledge and management. Transaction structures often involve direct agreements with biopharma companies and research institutions, highlighting the firm’s focus on B2B relationships. While specific pricing details for individual subscriptions or partnership agreements are not disclosed, the offerings are designed to provide scalable solutions for companies aiming to accelerate their product development timelines. In May 2025, QbDivision, Inc.

raised USD 13. 00 mn in venture funding, which will be strategically utilized to enhance product offerings and expand market reach. The company plans to launch new features designed to improve user experience and streamline operations by the end of 2025. Additionally, they are targeting expansion into new geographic regions, specifically aiming to increase their presence in Europe and Asia by 2026.

The recent funding will support the development of new products and facilitate entry into these promising markets.